Oxford BioMedica (OXOA) Financial Statements
Oxford BioMedica Financial Overview
Oxford BioMedica's market cap is currently $779.85M. The company's EPS TTM is $-0.35; its P/E ratio is -15.60; Oxford BioMedica is estimated to report earnings on April 15, 2027, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 168.74M | $ 128.80M | $ 89.54M | $ 139.99M | $ 142.80M |
| Gross Profit | $ 65.98M | $ 53.02M | $ 39.73M | $ 69.18M | $ 82.64M |
| Operating Income | $ -29.61M | $ -39.38M | $ -184.17M | $ -30.22M | $ 20.77M |
| EBITDA | $ -9.12M | $ -15.00M | $ -148.62M | $ -10.86M | $ 33.22M |
| Net Income | $ -30.13M | $ -43.19M | $ -157.49M | $ -39.16M | $ 19.01M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 96.88M | $ 60.65M | $ 103.72M | $ 141.31M | $ 109.02M |
| Total Assets | $ 325.72M | $ 231.64M | $ 252.34M | $ 460.18M | $ 237.23M |
| Total Debt | $ 148.13M | $ 108.76M | $ 111.46M | $ 114.28M | $ 9.34M |
| Net Debt | $ 51.24M | $ 48.11M | $ 7.74M | $ -27.00M | $ -99.60M |
| Total Liabilities | $ 234.37M | $ 171.16M | $ 174.51M | $ 223.99M | $ 49.89M |
| Stockholders' Equity | $ 91.35M | $ 57.05M | $ 74.01M | $ 204.65M | $ 187.34M |
| Cash Flow | |||||
| Free Cash Flow | $ -10.21M | $ -58.12M | $ -38.35M | $ -28.91M | $ 15.99M |
| Operating Cash Flow | $ -5.45M | $ -50.63M | $ -28.52M | $ -12.62M | $ 25.45M |
| Investing Cash Flow | $ -8.10M | $ 5.63M | $ 2.81M | $ -56.46M | $ -9.46M |
| Financing Cash Flow | $ 50.59M | $ 2.91M | $ -12.70M | $ 98.62M | $ 46.21M |
Currency in GBP